What Investors Got Wrong Before Bio-Techne's Rally

Investors who held Bio-Techne from the start of the year are up 22.2%, including dividends. If you had been weighing a position on 1 January 2026, you were choosing between bullish calls that pointed to expanding biotech demand and recurring consumables, and cautious views focused on weak funding, tariff risks, and commoditization. With that split now set against the outcome, which part of Bio-Techne’s business case would you revisit first?

Bio-Techne is not the only name tied to this theme. Zero in on 33 healthcare AI stocks and compare how each one is priced.

Two Stories Bio-Techne Investors Were Arguing Over

The shares cost US$58.81 at the start of the period, and Bio-Techne sat between two very different storylines about where its tools and reagents business might head next.

On the bullish side, one narrative pointed to a Fair Value of US$80, a price implied by expectations that rising healthcare spending and aging populations would support faster adoption of its platforms and recurring consumables.

The cautious view suggested a Fair Value of US$54.08, anchored in worries that US funding uncertainty, tariff risks, and pressure on healthcare budgets could restrain demand and squeeze profitability.

What The Results Changed For The Bio-Techne Debate

The clearest development was Bio-Techne swinging from a loss of US$17.7 million in Q4 2025 to net income of US$54.64 million in Q4 2026, which backed the optimistic argument that margins could improve. Revenue moved from US$316.964 million to US$321.192 million, so the jump in net margin from a 5.6% loss to a 17.0% profit supported the bullish profitability story more than the cautious case.

The lesson is simple. When a thesis hinges on margin resilience, do not stop at top-line trends. Track net income and net margin together, quarter by quarter, to see whether efficiency claims are actually turning into cash-generative businesses.

What Bio-Techne’s Recent Run Already Prices In

Bio-Techne now trades at US$72.57, after a 22.2% gain from the start of the year. The selected Narrative’s Fair Value sits below the current price and frames that gap around execution on Merck KGaA’s integration plan and product mix pressures.

At this level, a buyer is effectively assuming Bio-Techne turns stronger interest in proteomic and cell therapy tools into durable organic growth while preserving margins. This raises the question of how the highlighted integration risks and customer spending patterns could challenge that outcome.

"The main thing that has to go right is for Bio-Techne to convert stronger engagement in proteomic analysis, spatial biology and cell therapy tools into sustained higher organic revenue growth without eroding its sector-leading margins. The numbers imply that Bio-Techne’s share price already reflects a successful recovery and a full takeover premium following Merck KGaA’s agreed all-cash offer at US$73 per share, which may leave limited room for further upside based on fundamentals."

That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for

Looking Beyond Bio-Techne’s Lab Bench

Watching Bio-Techne, you are really watching healthcare’s appetite for better tools. Nearby sits a business focused on treatments and procedures themselves.

That group has built a broad set of drugs and devices across cancer, immune disorders, brain health, heart disease, surgery and vision.

Where Bio-Techne targets the research and testing side, this other player aims to turn lab insight into therapies and operating room hardware.

Its push into complex medicines, premium surgical systems and higher value eye products keeps raising a practical question.

How might demand for measurable outcomes reshape returns across both ends of this healthcare chain?

The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 25% above its price

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com